The North America Opioid Use Disorder (OUD) Market should witness market growth of 9.3% CAGR during the forecast period (2023-2030).
Opioids are a kind of medicine used to relax muscles, lessen pain, and reduce stress. Opioid use disorder is a long-lasting, recurring brain disorder distinguished by excessive opioid use. It is categorized as a neurological disorder because it involves functional changes to brain circuits involved in motivation, stress, self-control, and decision-making and because these changes may last for a long period after drug use has stopped. Opioid use disorder is characterized by an intense desire to use opioids, increased opioid tolerance, and withdrawal symptoms after ceasing consumption. Many governments, like the U.S., have implemented measures to effectively handle this condition to lessen the risk. Along with the increasing number of new products being released by large corporations, these legislative changes are projected to positively affect the market.
The U.S. Food and Drug Administration (FDA) has already authorized the safe and highly effective drugs methadone, buprenorphine, and extended-release naltrexone to treat OUD. By easing withdrawal symptoms and decreasing opioid cravings, these medications decrease the likelihood that people with OUD would resume drug use and lessen the chance of a fatal overdose. These drugs also aid in functional recovery, quality-of-life enhancement, and integration into families and communities. These drugs save lives because they are evidence-based, secure, and highly effective.
The opioid crisis, in accordance with the Canadian government, has brought to light the adverse consequences that opioids are having on individuals, families, and communities across Canada. More than 9,000 alleged opioid-related deaths have occurred since 2016. About 11 people per day died from opioid overdoses in 2017. Numerous individuals have required hospitalization due to an opioid overdose. A total of $359.2 million over five years has been funded in the budget for 2023 to fund the Canadian Drugs and Substances Strategy (CDSS). It adds to over $800 million spent fighting the overdose issue since 2017. It is predicted that the market for opioid use disorders will expand as the number of opioid addicts increases in the region.
The US market dominated the North America Opioid Use Disorder (OUD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,946.3 million by 2030. The Canada market is estimated to grow at a CAGR of 11.8% during (2023-2030). Additionally, The Mexico market should witness a CAGR of 10.8% during (2023-2030).
Based on Drug Class, the market is segmented into Buprenorphine, Methadone and Naltrexone. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies & Stores and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Indivior PLC (Reckitt Benckiser Group plc), Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.), Orexo AB (Orexo US, Inc.), Alkermes PLC, Titan Pharmaceuticals, Inc., Camurus AB, AstraZeneca PLC, Hikma Pharmaceuticals PLC, Mallinckrodt PLC , and Viatris, Inc.
Opioids are a kind of medicine used to relax muscles, lessen pain, and reduce stress. Opioid use disorder is a long-lasting, recurring brain disorder distinguished by excessive opioid use. It is categorized as a neurological disorder because it involves functional changes to brain circuits involved in motivation, stress, self-control, and decision-making and because these changes may last for a long period after drug use has stopped. Opioid use disorder is characterized by an intense desire to use opioids, increased opioid tolerance, and withdrawal symptoms after ceasing consumption. Many governments, like the U.S., have implemented measures to effectively handle this condition to lessen the risk. Along with the increasing number of new products being released by large corporations, these legislative changes are projected to positively affect the market.
The U.S. Food and Drug Administration (FDA) has already authorized the safe and highly effective drugs methadone, buprenorphine, and extended-release naltrexone to treat OUD. By easing withdrawal symptoms and decreasing opioid cravings, these medications decrease the likelihood that people with OUD would resume drug use and lessen the chance of a fatal overdose. These drugs also aid in functional recovery, quality-of-life enhancement, and integration into families and communities. These drugs save lives because they are evidence-based, secure, and highly effective.
The opioid crisis, in accordance with the Canadian government, has brought to light the adverse consequences that opioids are having on individuals, families, and communities across Canada. More than 9,000 alleged opioid-related deaths have occurred since 2016. About 11 people per day died from opioid overdoses in 2017. Numerous individuals have required hospitalization due to an opioid overdose. A total of $359.2 million over five years has been funded in the budget for 2023 to fund the Canadian Drugs and Substances Strategy (CDSS). It adds to over $800 million spent fighting the overdose issue since 2017. It is predicted that the market for opioid use disorders will expand as the number of opioid addicts increases in the region.
The US market dominated the North America Opioid Use Disorder (OUD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,946.3 million by 2030. The Canada market is estimated to grow at a CAGR of 11.8% during (2023-2030). Additionally, The Mexico market should witness a CAGR of 10.8% during (2023-2030).
Based on Drug Class, the market is segmented into Buprenorphine, Methadone and Naltrexone. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies & Stores and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Indivior PLC (Reckitt Benckiser Group plc), Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.), Orexo AB (Orexo US, Inc.), Alkermes PLC, Titan Pharmaceuticals, Inc., Camurus AB, AstraZeneca PLC, Hikma Pharmaceuticals PLC, Mallinckrodt PLC , and Viatris, Inc.
Scope of the Study
By Drug Class
- Buprenorphine
- Methadone
- Naltrexone
By Route of Administration
- Parenteral
- Oral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Stores
- Online Pharmacies
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Indivior PLC (Reckitt Benckiser Group plc)
- Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
- Orexo AB (Orexo US, Inc.)
- Alkermes PLC
- Titan Pharmaceuticals, Inc.
- Camurus AB
- AstraZeneca PLC
- Hikma Pharmaceuticals PLC
- Mallinckrodt PLC
- Viatris, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. North America Opioid Use Disorder (OUD) Market by Drug Class
Chapter 5. North America Opioid Use Disorder (OUD) Market by Route of Administration
Chapter 6. North America Opioid Use Disorder (OUD) Market by Distribution Channel
Chapter 7. North America Opioid Use Disorder (OUD) Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Indivior PLC (Reckitt Benckiser Group plc)
- Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
- Orexo AB (Orexo US, Inc.)
- Alkermes PLC
- Titan Pharmaceuticals, Inc.
- Camurus AB
- AstraZeneca PLC
- Hikma Pharmaceuticals PLC
- Mallinckrodt PLC
- Viatris, Inc.
Methodology
LOADING...
